Opinion
Time for India to be firm with drugmakers rather than deregulate
Lax stance risks opportunity for 'friend-shoring' to serve Western nations
Treatment would give women option other than surgical procedure
Contaminated over-the-counter medicines killed 300-plus children in 2022
Leqembi's price point spurs optimism after Aduhelm, but wide use unclear
Pandemic saps resources to protect infants from contagious diseases
Structure Therapeutics developing drugs targeting a wide range of chronic diseases
Drugmaker's move follows U.S. application for full FDA approval
Executive vice president wishes for a 'clear path' into China as demand wanes
Lower cost could help spread use but better testing is key, analysts say
Company's COVID drug in high demand as infections spread following policy U-turn
Japanese company to revamp supply chain, turns to India and Japan for chemicals
FDA-approved treatment will save money spent on nursing care: Eisai CEO
Shionogi and KM Biologics also eye homegrown shots targeting variants
U.S. authorization of Leqembi follows setbacks with Aduhelm
U.S. drugmaker sees promise in target company's technologies
Drugmaker pursues first overseas authorization for Xocova treatment
Agreement with Sino Bio unit comes a month after antiviral drug's approval in Japan
Allegations echo Gambia scandal, casting new doubts on 'pharmacy of the world'
Advent actively investing in Indian companies
Official count remains low, but country likely seeing 5,000 deaths a day
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.